Prothena (PRTA) to Release Quarterly Earnings on Thursday

Prothena (NASDAQ:PRTA) is projected to post its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Prothena to post earnings of ($0.31) per share and revenue of $0.8090 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:00 PM ET.

Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. Prothena had a negative return on equity of 65.89% and a negative net margin of 2,520.57%.The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.67 million. On average, analysts expect Prothena to post $1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Prothena Price Performance

Shares of NASDAQ PRTA opened at $10.64 on Friday. The business’s 50-day moving average price is $9.80 and its two-hundred day moving average price is $9.79. Prothena has a one year low of $4.32 and a one year high of $11.69. The company has a market capitalization of $572.75 million, a P/E ratio of -2.34, a price-to-earnings-growth ratio of 0.37 and a beta of -0.23.

Hedge Funds Weigh In On Prothena

Several large investors have recently made changes to their positions in PRTA. Jacobs Levy Equity Management Inc. acquired a new position in shares of Prothena during the 1st quarter worth about $230,000. Creative Planning lifted its position in shares of Prothena by 373.0% during the 2nd quarter. Creative Planning now owns 50,569 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 39,879 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Prothena by 72.1% during the 2nd quarter. American Century Companies Inc. now owns 59,965 shares of the biotechnology company’s stock worth $364,000 after purchasing an additional 25,129 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Prothena by 7,956.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 96,196 shares of the biotechnology company’s stock worth $584,000 after purchasing an additional 95,002 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its position in shares of Prothena by 251.8% during the 2nd quarter. Hsbc Holdings PLC now owns 46,047 shares of the biotechnology company’s stock worth $282,000 after purchasing an additional 32,959 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on PRTA. Citigroup reaffirmed a “market outperform” rating on shares of Prothena in a research report on Friday, March 13th. Royal Bank Of Canada boosted their price target on Prothena from $11.00 to $12.00 and gave the stock a “sector perform” rating in a research report on Friday, February 20th. Weiss Ratings cut Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. Finally, Stifel Nicolaus set a $19.00 price target on Prothena in a research report on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $21.67.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.